 |
Carbovir |
|---|---|
| Trade Name | |
| Orphan Indication | Persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3 |
| USA Market Approval | USA |
| USA Designation Date | 1989-12-13 00:00:00 |
| Sponsor | Glaxo Wellcome Inc.;5 Moore Drive;Research Triangle Park, North Carolina, 27709 |
